Prescribing Trends and Associated Outcomes of Antiepileptic Drugs in US Nursing Homes Surrounding the COVID-19 Pandemic

StatusEnrolling by Invitation
PhaseNot specified
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 5 months later Jun 30, 2026 → Nov 30, 2026
See other at-risk trials from Virginia Commonwealth University

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion pushed from Jun 30, 2026 to Nov 30, 2026
    • Eligibility criteria expanded, about 8 words
    • Secondary endpoints: details revised at 1 of 2 entries
  2. 2 versions Re-verified since Oct 29, 2024, no change to tracked fieldsv2-v3
  3. Study First Submitted
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Since the "National Partnership to Improve Dementia Care" debuted in 2012, almost all long-stay psychoactive prescribing has been graded by CMS, which has correlated to decreased use. However, some national data suggest that while these psychoactive medications are being used less, prescriptions of mood-stabilizing antiepileptic drugs (AEDs) have increased. Unlike all other psychoactive medications, AEDs prescribed in nursing homes are not mandatorily reported to CMS or graded in a quality-measure.
Trial Details
NCT Number NCT06095284
Lead Sponsor Virginia Commonwealth University
Collaborators: National Institute on Aging (NIA)
Conditions
(from sponsor)		 Dementia
Related terms Dementia
Enrollment 22,500,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov